

CONFIDENTIAL

M12401

Glaxo Wellcome Research and Development

Table 7: Tumour Incidences

0078 S3074
PLACES V8.400
page 9
56-330-9

GR68755C: Oral (drinking water) oncogenicity study in B6C3F1 mice
Study numbers H12401
INCIDENCE OF TUMOURS
SURVIVORS AND DECEDENTS COMBINED

TUMORS	GROUP	INCIDENCE OF TUMORS (NUMERIC)											
		MALES						FEMALES					
		Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	#	Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	#
Pancreas:													
Islet-cell adenoma (8)		(59)	(60)	(60)	(60)	(60)	# (59)	(60)	(59)	(60)	(60)	(60)	
Pituitary:													
adenoma (8)		(60)	(60)	(59)	(58)	(57)	# (58)	(58)	(58)	(58)	(58)	(58)	(59)
pars intermedia adenoma (8)							# 1	5	3	6	5		
Seminal vesicles:													
hemangioma (8)		(60)	(60)	(60)	(60)	(60)	# (60)	(60)	(60)	(60)	(60)	(60)	(60)
Skeletal muscle:													
hemangioma (8)		(60)	(60)	(60)	(60)	(60)	# (60)	(60)	(60)	(60)	(60)	(60)	1

Figures in brackets represent the number of animals from which this tissue was examined microscopically. The absence of a numeral indicates that the lesion specified was not encountered.
[B] = Benign [M] = Malignant

THE SUBJECT OF THE PRESENT

Final Report
N12401

Final Report

APPEARS THIS WAY

Glaxo Wellcome Research and Development

CONFIDENTIAL

WPT/93/360
M12401

Table 7: Tumour Incidences

6-DEC-95
page 7
PLACES VB.400

GR6873C: Oral (drinking water) oncogenicity study in B6C3F1 mice
Study number: M12401
INCIDENCE OF TUMOURS
SURVIVORS AND DECEDENTS COMBINED

TUMOURS	INCIDENCE OF TUMOURS (NUMERIC)												
	GROUP	MALES						FEMALES					
		Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	#	Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	#
Skeleton:													
osteosarcoma (M)		(8)	(11)	(2)	(7)	(8)	# (46)	(43)	(45)	(51)	(47)	#	
metastasizing osteosarcoma (M)					1		#		1			#	
hemangioma (S)		(60)	(60)	(58)	(59)	(60)	# (60)	(60)	(60)	(60)	(60)	# (60)	
Skin:							#					#	
squamous papilloma (S)					1		#				1	#	
sebaceous adenoma (S)							#			1		#	
fibroma (S)		1	1				#					#	
sarcoma (M)		1	2				#	1	1			#	
fibrosarcoma (M)							#					#	

figures in brackets represent the number of animals from which this tissue was examined microscopically
The absence of a numeral indicates that the lesion specified was not encountered
(S) = Benign (M) = Malignant

M12401 Final Report

APPEARS THIS WAY
ON ORIGINAL

CONFIDENTIAL
Glaxo Wellcome Research and Development

WPT/83/360
M12401

Table 7: Tumour Incidences

BEST POSSIBLE COPY

6-DEC-95
Page 8
PLACES VB.400

GR68755G: Oral (drinking water) oncogenicity study in B6C3F1 mice
Study number M12401
INCIDENCE OF TUMOURS
SURVIVORS AND DECEDENTS COMBINED

TUMOURS	GROUP	INCIDENCE OF TUMOURS (NUMERIC)					
		MALES			FEMALES		
		Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	
Skin:							
Lymphangione (B)			1	(60)	(59)	(60)	(60)
Haemangioma (B)							
Small Intestines:							
adenocarcinoma (M)		(54)	(58)	(59)	(59)	(56)	(60)
Soft tissues:		(2)		(1)		(1)	(1)
Lipoma (B)		2		1			
Spleen:		(60)	(60)	(60)	(60)	(59)	(60)
Haemangioma (B)		4	3	4	4	2	2

Figures in brackets represent the number of animals from which this tissue was examined microscopically.
The absence of a numeral indicates that the lesion specified was not encountered
(B) = Benign (M) = Malignant

M12401 Final Report

APPEARS THIS WAY
ON ORIGINAL

Glaxo Wellcome Research and Development

CONFIDENTIAL

WPT/93/360
M12401

Table 7: Tumour Incidences

6-DEC-95
page 9
PLACES VO.400

GR68755C: Oral (drinking water) oncogenicity study in B63F1 mice
Study number: M12401
INCIDENCE OF TUMOURS
SURVIVORS AND DECEDENTS COMBINED

TUMOURS	GROUP	INCIDENCE OF TUMOURS (NUMERIC)									
		MALES					FEMALES				
		Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg
Stomach:											
squamous papilloma (S)		(59)	(59)	(60)	(60)	(60)	(60)	(60)	(59)	(60)	(60)
Testes:											
Interstitial-cell tumour (S)											
Interstitial-cell tumour (M)											
Thyroids:											
follicular adenoma (S)											
follicular carcinoma (M)											
c-cell adenoma (S)											

figures in brackets represent the number of animals from which this tissue was examined microscopically
The absence of a numeral indicates that the lesion specified was not encountered
(S) = Benign (M) = Malignant

M12401 Final Report

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Glaxo Wellcome Research and Development

CONFIDENTIAL

WPT/93/360
M12401

Table 7: Tumour Incidences

4-DEC-93
page 10
PLACES V6.400

G66753C Oral (drinking water) oncogenicity study in B6C3F1 mice
study number: M12401
INCIDENCE OF TUMOURS
SURVIVORS AND DECEDENTS COMBINED

TUMOURS	GROUP	INCIDENCE OF TUMOURS (NUMERIC)									
		MALES					FEMALES				
		Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg	Top water	Acid/d water	1.0 mg/kg	5.5 mg/kg	30.0 mg/kg
Uterus:											
stromal polyp (S)											
adenomatous polyp (S)											
adenocarcinoma (M)											
leiomyoma (S)											
leiomyosarcoma (M)											
hemangioma (S)											
Vagina:											
hemangioma (S)											

figures in brackets represent the number of animals from which this tissue was examined microscopically
The absence of a numeral indicates that the lesion specified was not encountered
(S) = Benign (M) = Malignant

M12401 Final Report

APPEARS THIS WAY
ON ORIGINAL

Appendix IV

Tumor and Non-Tumor Data of the Rat Carcinogenicity Study

Print No: 0045

TABLE 10f

Histopathology - group distribution of non-neoplastic findings for all animals

Printed: 12-APR-95
Page: 1

Group Compound 1 Control 2 3 4
Dose (mg/kg/day) 0 1.0 6.5 40.0

Schedule numbers GLX 041

... NUMBER OF ANIMALS AFFECTED ...

SEX:	MALE				FEMALE				
	GROUP	1	2	3	4	1	2	3	4
ORGAN AND FINDING DESCRIPTION	NUMBER	120	60	60	60	120	60	60	60
ADRENAL GLAND	NUMBER EXAMINED	120	60	60	60	120	60	60	60
TOP OF LIP									
CORTICAL FAT VACUOLATION		40	21	25	22	7	40	97	49
CORTICAL MACROPHAGIC DEGENERATION		1	3	4	0	0	0	0	1
EXTRAMEDULLARY HAEMOPOIESIS		0	0	0	0	0	0	0	0
CORTICAL BROWN ATROPHY		1	1	0	1	0	1	0	0
CORTICAL HYPERTROPHY		6	4	7	6	5	0	0	2
FOCAL CORTICAL HYPERPLASIA		0	0	0	0	0	0	0	1
FOCAL LYMPHOCTIC INFILTRATION		0	0	0	0	0	0	0	1
CORTICAL MINERALISATION		0	0	0	0	1	0	0	0
ADRENAL MED LER	NUMBER EXAMINED	120	60	60	60	120	60	60	60
FOCAL MEDULLARY HYPERPLASIA		9	6	4	4	1	0	0	0
BRAIN X 3	NUMBER EXAMINED	120	60	60	60	120	60	60	60
DEPRESSION DUE TO ENLARGED PITUITARY		8	9	10	6	10	18	7	10
HAEMORRHAGE		0	0	0	1	0	0	0	1
DILATED VENTRICLES		1	1	0	0	0	2	0	0
CHOLESTEROL GRANULOMA		0	0	0	1	0	0	0	0
OEDEMA		0	0	0	1	0	0	0	0
FOCAL GLIOSIS		1	0	0	0	0	0	0	0
CAECUM	NUMBER EXAMINED	120	60	60	60	120	60	60	60
SUBMUCOSAL OEDEMA		0	0	0	0	1	0	0	0
MUCOSAL ACUTE INFLAMMATION		0	0	0	1	0	0	0	0
ULCER(S)		0	1	0	0	0	0	0	0
SUBMUCOSAL CHRONIC INFLAMMATION		0	0	0	0	0	0	0	1
ARTERITIS		0	0	0	0	1	0	0	0
COLON	NUMBER EXAMINED	120	60	60	60	120	60	60	60
DILATED		1	1	0	1	0	0	0	0

Significant when compared with Group 1: a - p<0.05; c - p<0.001

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

NDA 21,107
Page 155

Print No: 0045

TABLE 10f - continued.

Histopathology - group distribution of non-neoplastic findings for all animals

Printed: 12-APR-95
Page: 2

Group: 1 1 2 3 4
Compound: Control 0 1.0 6.5 40.0
Dose (mg GR48755X/kg/day):

Schedule number: 01X 041

NUMBER OF ANIMALS AFFECTED

SEX: MALE FEMALE
GROUP: 1 2 3 4 1 2 3 4

NUMBER: 120 60 60 120 60 60 120 60

ORGAN AND FINDING DESCRIPTION

DUODENUM NUMBER EXAMINED: 119 60 60 60 120 60 60 60
--SUBMUCOSAL CHRONIC INFLAMMATION

EPIDIDYMIDES LER NUMBER EXAMINED: 119 60 60 59 0 0 0 0
--REDUCED SPERM CONTENT
--ARTERITIS

FEMUR INC. JT X2 NUMBER EXAMINED: 119 60 60 60 120 60 60 60
--SCLEROSIS
--OSTEODYSTROPHIA FIBROSA
--ARTICULAR CARTILAGE PROLIFERATION
--NARROW HAEMORRHAGE
--MISTOCTIC INFILTRATION

HEART, AURICLE NUMBER EXAMINED: 120 60 60 58 120 60 60 60
--ACUTE PERICARDITIS

HEART, VENTRICLE NUMBER EXAMINED: 120 60 60 60 120 60 60 60
--CHRONIC MYOCARDITIS
--MYOCARDIAL MINERALISATION
--VASCULAR MINERALISATION
--VALVULAR THICKENING
--ARTERITIS
--CHRONIC ENDOCARDITIS

ILEUM NUMBER EXAMINED: 120 60 60 60 120 60 60 60
--ULCER(S)
--VILLOUS STUNTING
--DILATED

KIDNEYS (LAR) NUMBER EXAMINED: 120 60 60 60 120 60 60 60
--PROGRESSIVE (SERULE) NEPHROPATHY
.. CONTINUED ON NEXT PAGE ..

Significant when compared with Group 1: a - p<0.05; c - p<0.001

G&R Report No: WPT/93/134

Report 93/0903

0185

APPEARS THIS WAY
ON ORIGINAL

TABLE 10F - continued.

histopathology - group distribution of non-neoplastic findings for all animals

Group	1	2	3	4
Compound	Control	...	GN4755C	
Dose (mg/kg/day)	0	1.0	6.5	40.0

W. H. 11

SEX:	MALE.....	FEMALE.....
GROUP: 1.	2.	4.
	1.	2.
	3.	4.

NUMBER: 120 40 40 40 40 120 40 40 40 60

1000

0
1
2
3
4
5
6
7
8
9

NO
NO
NO
NO
NO
NO
NO

NO
DO
DO
DO
DO
DO
DO

0
1
2
3
4
5
6
7
8
9

NO
OO
-O
W-
-O
OO
OO
-O

00000000

0
0
0
-
0
0
0
-

100-443887-100

2
17
16
23

2
17
16
23

0000000000

0
0
0
0
0
0
-

[illegible][illegible]

THE

© 2000 by John Wiley & Sons, Inc.

Significant when compared with Group 1: a - $p < 0.05$

APPEARS THIS WAY
ON ORIGINAL

Print No: 0043

Printed: 12-APR-95
Page: 4

Schedule number: ALX 041

GGR Report No: WPT/93/134

BEST POSSIBLE COPY

TABLE 10F - continued.

Histopathology - group distribution of non-neoplastic findings for all animals

Group: 1 Control 2 3 4
Compound: 0 1.0 6.5 40.0
Dose (mg/kg/day): 0 1.0 6.5 40.0

--- NUMBER OF ANIMALS AFFECTED ---

SEX: --- MALE --- FEMALE ---
GROUP: 1 2 3 4 1 2 3 4

NUMBER: 120 40 60 120 59 59 40

ORGAN AND FINDING DESCRIPTION

L M MESENTERIC NUMBER EXAMINED: 120 40 60 120 59 59 40

--PARAFOLLICULAR HYPERPLASIA 2 10 7 8 4 9 4

--SINUS HISTIOCYTOSIS 1 1 1 3 2 1 0

--LYMPHOCTOSIS 1 0 1 0 0 0 0

--HAEMORRHAGE 2 0 0 0 0 0 0

--CHRONIC LYMPHADENITIS 1 0 0 0 0 0 0

--ERYTHROCYTES AND ERYTHROPHAGOCYTOSIS IN SINUSES 25 8 9 16 10 4 4

--ARTERITIS 1 0 0 1 0 0 0

--DILATED SINUSES 10 1 2 1 1 0 0

--PLASMACYTOSIS 1 0 0 0 1 0 0

--ANGIECTASIS 0 0 0 0 1 0 0

LEFT EYE NUMBER EXAMINED: 114 60 40 57 120 40 40

--RETINAL FOLDS 0 0 0 0 0 1 0

--CHRONIC KERATITIS 3 2 1 0 0 0 1

--RETINAL DEGENERATION 2 0 0 0 1 0 0

--DISRUPTION/FIBROSIS 0 0 0 1 0 0 0

--ACUTE KERATITIS 1 1 0 0 0 0 0

--PUS IN ANTERIOR CHAMBER 1 0 0 0 0 0 0

--LENTICULAR DEGENERATION 1 0 0 0 0 1 0

LIVER X 2 NUMBER EXAMINED: 120 40 40 120 60 40 40

--BASOPHILIC FOCUS 7 2 0 3 19 4 15

--BASOPHILIC FOCI 1 0 3 3 13 6 7

--CLEAR CELL FOCUS/FOCI 3 3 3 3 13 6 7

--EOSTINOPHILIC FOCUS/FOCI OF HEPATOCELLULAR ALTERATION 42 25 19 33 16 7 8

--PORTAL TRACT (SERULE) CHANGE INCLUDING PROLIFERATION OF BILE 7 0 2 3 3 0 1

--DUCTS, MYALINE DEGENERATION AND INFLAMMATION 43 31 31 35 57 23 19

--EXTRAMEDULLARY HAEMOPOIESIS 1 0 0 0 0 0 0

--FOCAL NECROSIS 1 0 1 0 3 2 2

--PERITACINAR COAGULATIVE NECROSIS 9 9 2 9 9 2 3

--LOBAR (TORISON) NECROSIS 1 0 0 1 2 0 0

** CONTINUED ON NEXT PAGE **

Significant when compared with Group 1: a - p<0.05; b - p<0.01; c - p<0.001

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Print No: 0045

Printed: 12-APR-95
Page: 5

GGR Report No: WPT/93/134

TABLE 10F - continued.
Histopathology - group distribution of non-neoplastic findings for all animals

GGR Report No: WPT/93/134

Group 1 2 3 4
 Compound --- GR68753C ---
 Dosage (mg GR68753/kg/day): 0 1.0 6.5 10.0

Page: 5

Schedule numbers GLX 041

--- NUMBER OF ANIMALS AFFECTED ---

SEX: --- MALE --- FEMALE ---
 GROUP: 1- 2- 3- 4- 1- 2- 3- 4-

NUMBER: 120 60 60 60 120 60 60 60

ORGAN AND FINDING DESCRIPTION

--- FROM PREVIOUS PAGE ---

LIVER X 2

NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--FOCAL CYSTIC DEGENERATION

--CENTRILACINAR HEPATOCTYTIC FATTY VACUOLATION

--PERIACINAR HEPATOCTYTIC FATTY VACUOLATION

--PANACINAR HEPATOCTYTIC FATTY VACUOLATION

--FOCUS OF HEPATOCTYTIC FATTY VACUOLATION

--MIDZONAL HEPATOCTYTIC FATTY VACUOLATION

--FINE VACUOLATION OF SINGLE HEPATOCTYTES

--FOCAL TELANGIECTASIS

--INCREASED APOPTOSIS

--CAPSULAR FIBROSIS

--CONGESTION

--CHRONIC INFLAMMATORY CELLS WITHIN THE PORTAL AREA

--MEDIAN LOBE ANOMALY

--HAEMORRHAGIC NECROSIS

--DISTENDED BILE DUCT

--BILIARY CYST(S)

--PIGMENT LADEN HEPATOCTYTES

--PIGMENT LADEN KUPFFER CELLS

--CHRONIC INFLAMMATION

--AREA OF VACUOLAR DEGENERATION

--PORTAL FIBROSIS

LUNGS X 2

NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--ALVEOLAR HAEMORRHAGE

--ACCUMULATION(S) OF ALVEOLAR MACROPHAGES

--PERIBRONCHIOAL LYMPHOCTYTES

--FOCAL ALVEOLAR WALL EPITHELIALISATION

--ALVEOLAR WALL MINERALISATION

--GENERAL VASCULAR MINERALISATION

--CHRONIC PNEUMONIA

--GRANULOMA(S)

** CONTINUED ON NEXT PAGE **
Significant when compared with Group 1: a - p<0.05; b - p<0.01

APPEARS THIS WAY
ON ORIGINAL

Print No: 0043

Printed: 12-APR-95
Page: 6

GGR Report No: WPT/93/134

BEST POSSIBLE COPY

TABLE 107 - continued.

Histopathology - group distribution of non-neoplastic findings for all animals

Group Compound 1 Control 2 3 4
Dose (mg/kg/day) 0 1.0 4.5 40.0

Schedule numbers GLX 041
Schedule numbers GLX 041

NUMBER OF ANIMALS AFFECTED

SEX:	MALE				FEMALE				
	GROUP:	1	2	3	4	1	2	3	4
ORGAN AND FINDING DESCRIPTION	NUMBER:	120	60	60	60	120	60	60	60
** FROM PREVIOUS PAGE **	NUMBER EXAMINED:	120	60	60	60	120	60	60	60
LUNGS X 2		0	1	0	0	0	0	0	0
--ALVEOLAR FLOODING		4	2	1	0	0	0	1	0
--FOCAL BONE									
MAMMARY A.CAUD	NUMBER EXAMINED:	120	60	60	60	119	59	59	60
--SECRETORY ACTIVITY		3	2	2	2	34	28	26	32
--ACTINAR HYPERPLASIA		1	0	0	0	39	23	17	15
--GALACTOCOELE(S)		0	0	0	0	0	0	0	1
ESOPHAGUS	NUMBER EXAMINED:	120	60	60	60	120	60	60	60
--ACUTE INFLAMMATION		0	1	0	0	0	0	0	0
--NECROSIS		0	1	0	0	0	0	0	0
OVARIES (L&R)	NUMBER EXAMINED:		0	0	0	120	60	60	60
--HAEMORRHAGE		0	0	0	0	0	0	0	1
--NUMEROUS CORPORA LUTEA		0	0	0	0	1	0	0	0
--BURSTAL CYST(S)		0	0	0	0	3	1	2	3
--SEITOLI CELL PROLIFERATION		0	0	0	0	2	1	0	0
--OVARIAN CYST		0	0	0	0	1	1	2	0
PANCREAS	NUMBER EXAMINED:	120	60	59	60	119	60	60	60
--ARTERITIS		18	7	3	3	1	0	0	0
--FOCAL EXOCRINE CELL HYPERPLASIA		17	12	13	13	2	3	6	5
--ISLET CELL HYPERPLASIA		0	2	1	0	3	1	1	1
--ACINAR ATROPHY WITH CHRONIC INFLAMMATION		2	0	1	1	0	1	1	1
--PERITONITIS		0	0	0	1	1	0	0	0
--HAEMORRHAGE		2	1	0	0	0	0	1	0
--VASCULAR MINERALISATION		1	1	0	0	0	0	0	0
--FIBROSIS		1	1	0	0	0	0	0	0
--DUCTULAR PROLIFERATION		1	1	0	0	1	0	0	0
--OEDEMA		0	0	0	0	0	2	0	0

Significant when compared with Group 1: a - p<0.05

APPEARS THIS WAY
ON ORIGINAL

BEST POSSIBLE COPY

Print No: 8045

TABLE 10f - continued.

Histopathology - group distribution of non-neoplastic findings for all animals

Printed: 12-APR-95
Page: 7

Group: 1 1 2 3 4
Compound: Control 0 1.0 6.5 40.0
Doseage (mg GR60755X/kg/day):

Schedule number: ELK 041

--- NUMBER OF ANIMALS AFFECTED ---

SEX: MALE.....FEMALE.....
GROUP: 1- 2- 3- 4- 1- 2- 3- 4-

NUMBER: 120 60 60 60 120 60 60 60

ORGAN AND FINDING DESCRIPTION

PARATHYROID GLAND NUMBER EXAMINED: 108 57 57 57 116 54 56 56

--HYPERPLASIA

PITUITARY NUMBER EXAMINED: 116 60 60 59 120 60 60 60

--FOCAL HYPERPLASIA

--HAEMORRHAGE

--CRANIOPHARYNGEAL CYST

--DUCTULAR REMNANTS WITHIN PARS NERVOSA

--HAEMOSIDERIN DEPOSITION

--FOCAL HYPERPLASIA OF PARS INTERMEDIA

--DEGENERATION

--DIFFUSE HYPERPLASIA

PROSTATE NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--ACUTE INFLAMMATION

--CHRONIC INFLAMMATION

--HYPERPLASIA

--ABSCESSES(ES)

RECTUM NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--SUBMUCOSAL ACUTE INFLAMMATION

--DILATED

SEMINAL VESICLES NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--LACKING SECRETION

--DILATED WITH SECRETION

--ACUTE INFLAMMATION

--CHRONIC INFLAMMATION

SKIN NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--SCABIES

--FOCAL COLLAGEN DEPOSITION

Significant when compared with Group 1: b - p<0.01

APPEARS THIS WAY
ON ORIGINAL

Print No: 0045

Printed: 12-APR-95
Page: 8

Schedule number: GLX 041

GGR Report No: WPT/93/134

BEST POSSIBLE COPY

TABLE 10F - continued.

Histopathology - group distribution of non-neoplastic findings for all animals

Group : 1 Control 2 3 4
Compound : --- GR60755C ---
Dose (mg GR60755X/kg/day): 0 1.0 6.5 40.0

... NUMBER OF ANIMALS AFFECTED ...

SEX: --- MALE --- FEMALE ---
GROUP: 1 2 3 4 1 2 3 4

NUMBER: 120 60 60 60 120 60 60 60

ORGAN AND FINDING DESCRIPTION

SPINAL C. CERV NUMBER EXAMINED: 119 60 60 60 120 60 60 60

--HAEMORRHAGE

SPINAL C. THOR NUMBER EXAMINED: 119 60 60 60 120 60 60 60

--HAEMORRHAGE

SPLEEN NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--EXTRAMEDULLARY HAEMOPOIESIS

--LYMPHOCTOLYSIS

--HAEMOSTEROSIS

--CONGESTION

--LYMPHOID HYPERPLASIA

--CAPSULAR FIBROSIS

--CAPSULAR CYST

--ABSCESS(ES)

STOMACH X 3 NUMBER EXAMINED: 120 60 60 60 120 60 60 60

--NO PYLORIC AREA

--GLANDULAR REGION: FIBROSIS OF LAMINA PROPRIA

--GLANDULAR REGION: DILATED GLANDS

--GLANDULAR REGION: MINERALISATION OF GLANDS

--GLANDULAR REGION: ACUTE INFLAMMATION

--GLANDULAR REGION: CHRONIC INFLAMMATION

--KERATINISED REGION: HYPERKERATOSIS AND ACANTHOSIS

--KERATINISED REGION: ACUTE INFLAMMATION

--KERATINISED REGION: CHRONIC INFLAMMATION

--KERATINISED REGION: MUCOSAL OEDEMA

--KERATINISED REGION: ULCER(S)

--MINERALISATION OF MUSCULARIS EXTERNA

--PERITONITIS

--MINERALISATION OF MUSCULARIS MUCOSA

--KERATINISED REGION: NECROSIS

--CONTINUED ON NEXT PAGE **

Significant when compared with Group 1: a - p<0.05

APPEARS THIS WAY
ON ORIGINAL

TABLE 101 - continued.

0192

Group	1	2	3	4
Compound	Control	---	0A48755C	----
Access (mg 0A48755X/kg/day)	0	1.0	6.5	40.0

Schedule number: SLX 041
.....
12 - A P P E E T E D - ..

SEX:	MALE	FEMALE
GROUP 1	1. -2. -3. -4.	1. -2. -3. -4.

NUMBER: 120 60 60 60 120 60 60 60

[illegible]

0
0
0
0
0
0
0
0

100-443887-100

120 40 40 40 0 0 0 0

32	23	29	20	00
38	25	17	12	00

[illegible]

0
0
0
0
-
0
0
0

[illegible]

0
-
0
2
-
7
6
6

20
40
10
00
00
10
20

[illegible]

1960
1961
1962
1963
1964
1965

FO
ON
OO
OO
OO
NO
OO
FO

	10	9	8	7	6	5	4	3	2	1	0
10	1	3	9	1	1	4	2	0	2	1	0

Significant when compared with Group 1: a - $p < 0.05$; b - $p < 0.01$

S
R
E
C

GGR Report No: WPT/93/134

BEST POSSIBLE COPY

Print No: 0045

Printed: 12-APR-95
Page: 10

GGR Report No: WPT/93/134

TABLE 10F - continued.

Histopathology - group distribution of non-neoplastic findings for all animals

Group Compound	1	2	3	4	Schedule number: GLX 041
Dose (mg GR6755X/kg/day):	Control	1.0	6.5	40.0	
					--- N U M B E R O F A N I M A L S A F F E C T E D ---
					SEX: --- MALE --- FEMALE ---
					GROUP: 1- 2- 3- 4- 1- 2- 3- 4-
					NUMBER: 120 60 60 60 120 60 60 60
ORGAN AND FINDING DESCRIPTION					
TONGUE					
--- ARTERITIS	119	60	60	120	60 60 60
--- ACUTE INFLAMMATION	7	6	3	3	0 0 0
--- ULCER(S)	0	0	1	0	0 0 0
--- VASCULAR MINERALISATION	0	0	1	0	0 0 0
--- ACANTHOSIS	1	2	0	0	0 0 0
--- HYPERKERATOSIS	0	0	0	0	0 0 0
URINARY BLADDER					
--- DILATED	120	60	60	118	60 59 59
--- ACUTE INFLAMMATION	2	1	1	0	0 0 0
--- MURAL HAEMORRHAGE	1	0	0	0	0 0 0
--- TRANSITIONAL CELL HYPERPLASIA	2	0	0	0	0 0 0
--- CHRONIC INFLAMMATION	4	2	2	0	0 0 0
--- CALCULUS/CALCULI	1	0	0	1	0 0 0
UTERINE CERVIX					
--- FOCAL STROMAL HYPERPLASIA	0	0	0	0	0 0 0
--- STROMAL HYPERPLASIA	0	0	0	0	0 0 0
UTERUS					
--- POLYPOID HYPERPLASIA	0	0	0	0	0 0 0
--- DILATED	0	0	0	0	0 0 0
--- ADENOMYOSIS	0	0	0	0	0 0 0
--- PURULENT INFLAMMATION	0	0	0	0	0 0 0
--- LUMINAL HAEMORRHAGE	0	0	0	0	0 0 0
VAGINA					
--- ACUTE INFLAMMATION	0	0	0	0	0 0 0
--- MUCIFICATION OF EPITHELIUM (DIOESTRUS)	0	0	0	0	0 0 0

APPEARS THIS WAY
ON ORIGINAL